Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
February 26 2024 - 7:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
biotechnology company developing first-in-classi targeted and
immune-mediated therapeutics to fight cancer, today announced that
Stephen Brady, president and chief executive officer of Tempest,
will present at the 44th Annual TD Cowen Healthcare Conference on
Monday, March 4, 2024 at 9:10 a.m. ET.
To access the live or archived recording of the presentation,
please visit the investor section of the Tempest website at
https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
biotechnology company advancing a diverse portfolio of small
molecule product candidates containing tumor-targeted and/or
immune-mediated mechanisms with the potential to treat a wide range
of tumors. The company’s novel programs range from early research
to later-stage investigation in a randomized global study in
first-line cancer patients. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Investor & Media Contacts
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Apr 2024 to May 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From May 2023 to May 2024